Stock Ratings / Health Care / CALC / financials

PHIO (37) TPST (34) BLRX (46) LTRN (31) ⌘ Pro Terminal →

CalciMedica Inc. (CALC) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$1.46 -16.57% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.41

CalciMedica Inc. (CALC) carries a Roarable Rating of D- (Sell) with 38/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (38/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • RED ALERT Cap $10.0M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on CALC Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is CALC stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, CalciMedica Inc. (NASDAQ: CALC) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 38/100 at a spot price of $1.46 (-16.57% 1D, market cap $10.0M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, CALC ranks #520 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does CALC compare to PHIO and TPST in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), CALC carries a Roarable D- (38/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, PHIO (Phio Pharmaceuticals Corp.) holds a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $10.0M) and TPST (Tempest Therapeutics Inc.) posts a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $9.9M). Among the 5-stock peer group, CALC leads on earnings multiple (N/A) while CALC leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for CALC?

▼

Per CALC's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001534133), CalciMedica Inc. generated $0 in revenue, -$29.6M in net income, and -$21.2M in free cash flow against $13.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $1.41 (-3.17%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (38/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.8% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-8.9% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CALC)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (38/100 Composite)

🔍 WHY CALC SCORES 38/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (26% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▲ #2 Bullish Driver: Macro Regime Fit+10/20 pts (26% of score)

FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 48.8 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$1.12-4.5% Next Q

Q2 (-2Q)

Grade E$1.07+22.4% Next Q

Q3 (-1Q)

Grade E$1.31+11.5% Next Q

Current

Grade D-$1.46-7.8% Hist 90D α

Trajectory: E (30) → D- (38)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a CALC Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While CALC currently carries a cautious 38/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.71) and Max Pain ($1.53) forces dealer call-delta covering toward $37.80.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $CALC• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “CALC Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 38%NO 62%Trade / Inspect Odds →

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How CALC Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$0 (0% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY23

Rev $4.00B

FY24

Rev $4.00B

FY25

Rev $4.00B

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$4.00B	52%	-0.6%	-$29.6M	-$21.2M	-45%
FY 2024	$4.00B	52%	-0.6%	-$13.7M	-$21.2M	-45%
FY 2023	$4.00B	52%	-1%	-$34.4M	-$25.7M	-35%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring CALC)

✓Walkthrough of CALC's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

CALC // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -50.00%⚡ TESTING RESISTANCE

2026-11-03O $1.75H $1.75L $1.46C $1.46VOL 112.2K

RES: $1.75SUP: $0.77SMA50: $1.71SMA200: $3.78

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

CALC Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 CALC Butterfly Map → + Track CALC →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on CALC today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for CALC. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for CALC today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CALC)

Health Care Rank #520 of 1016 ⚔️ PHIO vs CALC Full Matrix →

1. Head-to-Head Health Care Peer Comparison (CALC vs. PHIO, TPST, BLRX, LTRN)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, CalciMedica Inc. (CALC) ranks #520 by composite RQD confidence (38/100, grade D-) and #892 by equity capitalization ($10.0M). Within this direct 5-issuer industry benchmark cohort, CALC leads on earnings valuation at N/A trailing P/E, while CALC leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. BLRX currently holds the highest overall quantitative score in the immediate peer group at 46/100 (D) compared with CALC at 38/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
CALC ACTIVE CalciMedica Inc.	D-	38/100	—	—	-35.0%	-16.57%	$10.0M	Benchmark Subject
PHIO Phio Pharmaceuticals Corp.	D-	37/100	—	—	-35.0%	-0.30%	$10.0M	/phio-vs-calc →
TPST Tempest Therapeutics Inc.	E	34/100	—	—	-35.0%	-7.07%	$9.9M	/tpst-vs-calc →
BLRX BioLineRx Ltd.	D	46/100	—	—	—	-1.48%	$9.9M	/blrx-vs-calc →
LTRN Lantern Pharma Inc.	E	31/100	—	—	-35.0%	-9.60%	$9.9M	/ltrn-vs-calc →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001534133

In its most recent audited fiscal period (FY2025, filed 2025-12-31), CalciMedica Inc. (CALC) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$29.6M, operating cash flow of -$21.2M, and free cash flow of -$21.2M (-0.2% YoY). On the balance sheet, CALC closed FY2025 with $13.6M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$29.6M	-$21.2M	-$21.2M	$13.6M	—
FY2024 (FY)	2024-12-31	$0	-$13.7M	-$21.1M	-$21.2M	$19.8M	—
FY2023 (FY)	2023-12-31	$0	-$34.4M	-$25.7M	-$25.7M	—	—

3. CALC Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is CALC stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does CALC compare to PHIO and TPST in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for CALC?

Where is CALC trading relative to its 50-day, 200-day, and 52-week technical levels?

CALC last traded at $1.46 (-16.57% on volume of 112,196 shares), positioning the stock -14.62% below its 50-day simple moving average ($1.71) and -61.38% below its 200-day simple moving average ($3.78). Across its 52-week range of $1.00 to $36.00, CALC sits at the 1.3% percentile with a 14-day RSI of 48.8 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.28 to $1.64).

CALC Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

How profitable is CalciMedica Inc. (CALC)?

In FY 2025 (10-K), CALC converted $4.0B of revenue into a 52% gross margin, 0% operating margin, and $0 in free cash flow (0% FCF margin).

Direct Sub-Reports: CALC RQD Cockpit CALC 12M Forecast CALC Earnings & Move CALC Dividends & DRIP CALC Insiders & 13F CALC Whale Options CALC Profit Sankey CALC News & Why

ROARABLE RATING BRIEF • RQD 38/100 (D-) ✓ STAGE-C NUMBER FIREWALL VERIFIED

CALC — CalciMedica Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:51:20Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, CALC scores 41 out of 100 and carries a letter grade of D-, labeled "Roarable Sell — Vulnerable Balance Sheet & Flow." Across the five pillars:

Fundamental Cash Engine (8 / 20): The rating cites ROIC of -35% and an FCF yield of 0%. For a prospective investor, this indicates the business is not currently generating returns on invested capital or free cash flow, so value rests on future outcomes rather than current earnings power.
Whale 13F Flow (8 / 20): Scored on institutional accumulation and options positioning. The sub-score is below midpoint, suggesting limited institutional conviction signals in the data.
Insider Conviction (5 / 20): Scored on SEC Form 4 and Congressional PTR cluster flow. This is the weakest pillar, and the news wire independently reports a CFO resignation, which a cautious investor would weigh against this score.
Macro Regime Fit (10 / 20): Beta is 1.0, with sector sensitivity noted. The stock does not offer a clear macro-regime tailwind per the rating.
Forensic Balance Sheet (10 / 20): Per the rating, Altman Z is 2.5, Piotroski F is 2/9, and Debt/Equity is 0.5. The Piotroski score is weak, and the Altman figure should be interpreted within the rating's own framework.

Implications: Upside drivers would have to come from outside current cash generation (for example, pipeline or financing developments not captured in these sources). Valuation tradeoffs are severe given a $11.9M market cap alongside negative operating income. Second-order risks include financing dependence and management transition. This is an analytical summary, not personalized advice.

Financial Trend

Period	Revenue	Operating Income	Net Income	EPS	FCF	Cash	Debt
FY 2025	$0.0M	$-23.1M	$-29.6M	N/A	$-21.2M	$11.5M	N/A
FY 2024	$0.0M	$-24.2M	$-13.7M	N/A	$-21.2M	$7.9M	N/A
FY 2023	$0.0M	$-38.1M	$-34.4M	N/A	$-25.7M	N/A	N/A

Per the SEC financials, the company reported no revenue and operating losses in each period shown. Gross, operating, and net margins are each 0% per market data, and ROIC is -35%. Per the Roarable RQD rating, the Altman Z-Score is 2.5 and the Piotroski F-Score is 2/9. Debt/Equity is 0.5 per the rating; period-level debt is N/A in the financials.

Recent Catalysts & News Wire Analysis

CFO resignation (two notices): Marketscreener reports the resignation of Stephen Bardin as Chief Financial Officer and as Principal Accounting Officer and Principal Financial Officer, each effective October 15, 2026. Stock Titan separately reports a CFO giving resignation notice tied to another professional opportunity. This is a governance and continuity risk watch item.
Price action headlines: Kalkine reports the stock rose 15.07 percent pre-market with no fresh news. Benzinga lists CALC among health care stocks moving in pre-market trading. The market data shows a 5.42% change.
TradingView estimates: A TradingView item covers CALC estimates and institutional positioning; no specifics are provided in the summary.
Proprietary signals: None provided in the Butterfly graph.

Open Questions

What are CalciMedica's products, clinical pipeline, and revenue model, given zero reported revenue?
What is the reconciled market capitalization, given $0.0B in the profile versus $11.9M in market data?
What are the P/E, EPS, and EV/EBITDA metrics, which are absent for a loss-making company?
How will the CFO transition affect financial reporting and filing timeliness?
What is the cash runway against the reported FY 2025 operating loss and cash balance?

CALC Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for CalciMedica Inc. (CALC) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to CALC Debate Forum (3) ↓

🟡 MARKET WIRE TradingView • 16h ago

CalciMedica, Inc. Estimates – NASDAQ:CALC

TradingView report covering CalciMedica Inc. (CALC) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Kalkine • 19h ago

Is CalciMedica (NASDAQ:CALC) a Low-Priced Stock Worth Watching After Rising 15.07 Percent Pre-Market With No Fresh News?

Kalkine report covering CalciMedica Inc. (CALC) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Benzinga • 22h ago

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Benzinga report covering CalciMedica Inc. (CALC) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 1d ago

Another professional opportunity prompts the CFO of CalciMedica (CALC) to give resignation notice.

Stock Titan report covering CalciMedica Inc. (CALC) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE www.marketscreener.com • 1d ago

Calcimedica, Inc. Announces Resignation of Stephen Bardin as Chief Financial Officer, Effective October 15, 2026

www.marketscreener.com report covering CalciMedica Inc. (CALC) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Benzinga • 1d ago

12 Health Care Stocks Moving In Friday's After-Market Session

Benzinga report covering CalciMedica Inc. (CALC) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Benzinga • 1d ago

12 Health Care Stocks Moving In Monday's Pre-Market Session

Benzinga report covering CalciMedica Inc. (CALC) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST Benzinga • 1d ago

Why Inovio Pharmaceuticals Shares Are Trading Higher By Over 230%; Here Are 20 Stocks Moving Premarket

Inovio shares surged 230% premarket after FDA accelerated Voceryq approval; ClearOne and 22nd Century gained, while RedCloud fell 33.5%.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

CALC Bull vs. Bear Conversation Board — What's Your Call at $1.46?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON CALC 🐻 67% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $1.54 (-12.0%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is CALC (D- • RQD 41/100) a Buy at $1.75?

Welcome to the CALC (CalciMedica Inc.) Roar Pit. Current RQD Composite is 41/100 (Roarable Sell — Vulnerable Balance Sheet & Flow) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

BE BearTrap_Alert Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $1.40 (-20.0%)

Spot @ $1.75

Pump the brakes on CALC — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on CALC, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless CalciMedica Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

SI SiliconVal_Bull Verified K Arena Trader 🐂 BULLISH 🎯 Target: $2.24 (+28.0%)

Spot @ $1.75

CALC cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on CALC, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $1.75 (52-wk range $1.00 - $36.00), any beat on forward guidance forces shorts and underweight funds to chase.